Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed
the treatment of chronic myeloid leukemia. Unlike chronic myeloid leukemia, chronic …

Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its
ability to couple immune cell receptors to intracellular signaling pathways that regulate …

B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia
(CLL). Bruton tyrosine kinase (BTK) is essential to BCR signaling and in knockout mouse …

Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated
by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the …

SYK (spleen tyrosine kinase) is well-characterized in the immune system as an essential
enzyme required for signaling through multiple classes of immune recognition receptors. As …

Abstract The Bcl-2 antagonist ABT-199 (venetoclax) has demonstrated promising clinical
activity in patients with chronic lymphocytic leukemia (CLL). ABT-199 is strongly cytotoxic …

Simple Summary Protein phosphorylation is a key regulatory mechanism that controls a
wide variety of cellular responses. This process is catalysed by the members of the protein …

The microenvironment provides essential growth and survival signals to chronic lymphocytic
leukemia (CLL) cells and contributes to their resistance to cytotoxic agents. Pharmacologic …

Inhibition of antigen-dependent B-cell receptor (BCR) signaling is considered a promising
therapeutic approach in chronic lymphocytic leukemia (CLL), but experimental in vivo …

Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with
downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is …